$7.07
4.33% yesterday
Nasdaq, Jun 13, 10:03 pm CET
ISIN
US64049M2098
Symbol
NEO

NeoGenomics, Inc. Stock price

$7.07
-1.29 15.43% 1M
-10.66 60.12% 6M
-9.41 57.10% YTD
-6.35 47.32% 1Y
-21.06 74.87% 5Y
+1.25 21.48% 10Y
+6.62 1,471.11% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.32 4.33%
ISIN
US64049M2098
Symbol
NEO
Sector

Key metrics

Market capitalization $909.87m
Enterprise Value $1.09b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.63
P/S ratio (TTM) P/S ratio 1.35
P/B ratio (TTM) P/B ratio 1.02
Revenue growth (TTM) Revenue growth 10.10%
Revenue (TTM) Revenue $672.36m
EBIT (operating result TTM) EBIT $-85.10m
Free Cash Flow (TTM) Free Cash Flow $-32.37m
Cash position $358.08m
EPS (TTM) EPS $-0.61
P/E forward negative
P/S forward 1.22
EV/Sales forward 1.47
Short interest 5.89%
Show more

Is NeoGenomics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

NeoGenomics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a NeoGenomics, Inc. forecast:

8x Buy
53%
7x Hold
47%

Analyst Opinions

15 Analysts have issued a NeoGenomics, Inc. forecast:

Buy
53%
Hold
47%

Financial data from NeoGenomics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
672 672
10% 10%
100%
- Direct Costs 374 374
5% 5%
56%
298 298
17% 17%
44%
- Selling and Administrative Expenses 335 335
9% 9%
50%
- Research and Development Expense 34 34
22% 22%
5%
-71 -71
10% 10%
-11%
- Depreciation and Amortization 14 14
8% 8%
2%
EBIT (Operating Income) EBIT -85 -85
10% 10%
-13%
Net Profit -78 -78
8% 8%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about NeoGenomics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeoGenomics, Inc. Stock News

Neutral
Business Wire
17 days ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will debut its PanTracer Family and unveil the Paletrra platform at ASCO 2025, advancing precision oncology diagnostics.
Neutral
Business Wire
23 days ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay.
Neutral
Business Wire
25 days ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York.
More NeoGenomics, Inc. News

Company Profile

NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Head office United States
CEO Anthony Zook
Employees 2,200
Founded 1998
Website neogenomics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today